What's new? Log in Free sign up

Altimmune (ALT) News and press releases

Company Profile

News

From Benzinga Pro

7 Analysts Have This to Say About Altimmune

Analyst Ratings

JMP Securities Reiterates Market Outperform on Altimmune, Maintains $15 Price Target

News, Price Target, Reiteration, Analyst Ratings

JMP Securities analyst Jonathan Wolleben reiterates Altimmune (NASDAQ:ALT) with a Market Outperform and maintains $15 price target.

Benzinga's Top Ratings Upgrades, Downgrades For March 22, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

JMP Securities Reiterates Market Outperform on Altimmune, Maintains $26 Price Target

News, Price Target, Reiteration, Analyst Ratings

JMP Securities analyst Jonathan Wolleben reiterates Altimmune (NASDAQ:ALT) with a Market Outperform and maintains $26 price target.

Goldman Sachs Downgrades Altimmune to Neutral, Lowers Price Target to $6

News, Downgrades, Price Target, Analyst Ratings

Goldman Sachs analyst Corinne Jenkins downgrades Altimmune (NASDAQ:ALT) from Buy to Neutral and lowers the price target from $20 to $6.

Nasdaq Up Over 100 Points; Crude Oil Rises 2%

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Tuesday. The Dow traded up 0.41% to 32,376.61 while the NASDAQ rose 1.05% to 11,798.39. The S&P 500, also rose, gaining, 0.76% to 3,981.58.

12 Health Care Stocks Moving In Tuesday's Intraday Session

Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share.

Gold Drops Over 1%; Existing Home Sales Surge In February

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 200 points on Tuesday. The Dow traded up 0.65% to 32,455.57 while the NASDAQ rose 0.57% to 11,741.91. The S&P 500, also rose, gaining, 0.70% to 3,979.20.

US Stocks Open Higher; Nasdaq Jumps Over 100 Points

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.90% to 32,535.25 while the NASDAQ rose 1.05% to 11,798.59. The S&P 500, also rose, gaining, 1.04% to 3,992.47.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Altimmune Stock Is Diving: What's Going On?

News, Small Cap, Movers

Shares of clinical-stage biopharmaceutical company Altimmune Inc (NASDAQ: ALT) are trading lower Tuesday after the company announced results from an interim analysis of

Altimmune Announces Results From 12-Week Phase 1b Type 2 Diabetes Safety Trial; 7.7% (placebo-adjusted 8.5%) Weight Loss At 2.4 mg Dose At Week 12

Biotech, General

Phase 1b Type 2 Diabetes Safety Trial (Week 12 End-of-Study Analysis) 7.7% (placebo-adjusted 8.5%) weight loss at 2.4 mg dose at Week 12 Glycemic homeostasis maintained, with no significant changes in

Altimmune Announces Results From Week 24 Interim Analysis Of Pemvidutide MOMENTUM Phase 2 Obesity Trial; Mean Weight Loss 10.7% At 2.4 mg Dose At Week 24

Biotech, General

MOMENTUM Phase 2 Obesity Trial (Week 24 Interim Analysis of 160 Subjects) Mean weight loss of 10.7% (placebo-adjusted 9.7%) at 2.4 mg dose at Week 24 Mean weight loss

Analyst Ratings for Altimmune

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $50 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Patrick Trucchio reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $50 price target.

Looking Into Altimmune's Return On Capital Employed

Altimmune Q4 EPS $(0.43) Beats $(0.50) Estimate; Cash, Cash Equivalents & Short-Term Investments Of $184.9M

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.50) by 14 percent. This is a 24.56 percent increase over losses of $(0.57) per share from the same

Earnings Scheduled For February 28, 2023

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.

Earnings Outlook For Altimmune

Press releases

From Benzinga Pro

Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors

News, Management, Press Releases

GAITHERSBURG, Md., March 27, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Catherine Angell Sohn, Pharm.D. to its Board of

Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial

MOMENTUM Phase 2 Obesity Trial (Week 24 Interim Analysis of 160 Subjects) Mean weight loss of 10.7% (placebo-adjusted 9.7%) at 2.4 mg dose at Week 24Mean weight loss of 11.9% (placebo-adjusted 11.1%) in subjects

Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023

Earnings, Press Releases

GAITHERSBURG, Md., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2022 financial results

Altimmune Appoints Raymond Jordt as Chief Business Officer

News, Management, Press Releases

GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Raymond Jordt as Chief Business Officer, effective

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023

News, Health Care, Press Releases

GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Chairman and Co-Founder, Pinnacle Clinical

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.